Sai Parenterals Limited
451.50
INR
-16.10
(-3.44%)
ISIN
INE0H9F01037
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- Full Time Employees
- 289
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hyderabad India
- Website
- saiparenterals.com
- Similar Companies
- Business
- Sai Parenterals Limited is an India-based pharmaceutical company that specializes in the development, manufacturing, and commercialization of finished dosage formulations and contract development and manufacturing organization (CDMO) solutions. Founded in 2001 and headquartered in Hyderabad, India, the company operates across two principal business divisions: Branded Generic Formulations and CDMO Services. Its product and service portfolio includes sterile injectables, comprising small and large volume parenterals, liquid ampoules, lyophilized vials, dry powder injectables, and pre-filled syringes; solid oral dosage forms, comprising standard compressed tablets, film-coated tablets, modified-release formulations, and hard and soft gelatin capsules; oral liquid formulations, comprising medicinal syrups, suspensions, and oral solutions; topical dermatological products, comprising therapeutic creams, gels, and ointments; private-label and over-the-counter (OTC) consumer healthcare remedies; and end-to-end CDMO services, comprising pre-formulation research, analytical method validation, stability testing, regulatory dossier preparation, and commercial-scale toll manufacturing. The company manufactures therapeutics targeting multiple medical specialties, including cardiovascular health, anti-diabetics, neuropsychiatry, respiratory ailments, anti-infectives and antibiotics, oncology, gastroenterology, dermatology, and vitamins, minerals, and nutritional supplements (VMS). Sai Parenterals serves retail pharmacy chains, healthcare institutions, government agencies, and multinational pharmaceutical enterprises across domestic and international markets, including India, Australia, New Zealand, Southeast Asia, the Middle East, and Africa, supported by WHO-GMP certified manufacturing facilities located in Hyderabad, Telangana, and Ongole, Andhra Pradesh. In major recent corporate developments, Sai Parenterals completed its Initial Public Offering (IPO) in April 2026, listing its equity shares on the National Stock Exchange of India (NSE: SAIPARENT) and the BSE to raise approximately INR 409 crore to finance production capacity expansions, construct a dedicated research and development center, repay outstanding borrowings, and fund global operations. As part of its international growth strategy, the company established a wholly owned holding subsidiary in Singapore, Sai Parenterals Pte Limited, through which it acquired a 74.6% controlling stake in Australia-based Noumed Pharmaceuticals Pty Ltd. Under this ownership, Noumed secured an exclusive multi-year private-label supply agreement valued at approximately AUD 202 million over an initial 7.5-year term with a major Australian pharmacy group and is finalizing the construction and operational commissioning of a modern pharmaceutical manufacturing plant in Adelaide, South Australia, to enhance regional supply chain capabilities throughout the Asia-Pacific territory.